A comprehensive screening & evaluation platform for various therapeutic modalities

Leveraging over thirty years of experiences in immunology, oncology, antibody science, and protein engineering, we have built a comprehensive platform for in vitro assays, in vivo evaluation, antibody engineering, ADCs and cell therapies. This robust platform enables us to advance our FIC antibodies into a range of therapeutic modalities, including ADC, scFv, Fab and F(ab’)2 fragments, and CAR-T/CAR-NK cell therapies, to deliver more effective and safer treatments for different indications.